U.S. FDA Official Kicks Off India Compliance Workshops Stressing Quality
This article was originally published in PharmAsia News
The deputy director of the U.S. FDA's international office told drug makers at the first of a year's worth of workshops in India that they must be honest in stating what they will do and that they did it.
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.